Medroxyprogesterone

Revisión del 20:39 24 ene 2024 de Rossdonaldson1 (discusión | contribs.) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===Non-pregnant vaginal bleeding=== *'''20 mg PO TID for 7 days'''<ref name="ACOG" /> **76% success, median time 3 days *Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days **In a trial of 48 patients all had cessation in 5 days.<ref name="highdose">Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient...")
(difs.) ← Revisión anterior | Revisión actual (difs.) | Revisión siguiente → (difs.)

Administration

  • Type:
  • Dosage Forms:
  • Routes of Administration:
  • Common Trade Names:

Adult Dosing

Non-pregnant vaginal bleeding

  • 20 mg PO TID for 7 days[1]
    • 76% success, median time 3 days
  • Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days
    • In a trial of 48 patients all had cessation in 5 days.[2]
  • Contraindications

Pediatric Dosing

Special Populations

Pregnancy Rating

Lactation risk

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

See Also

References

  1. ↑ Error en la cita: Etiqueta <ref> no válida; no se ha definido el contenido de las referencias llamadas ACOG
  2. ↑ Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013. 208(6):499.e1-e5.
Obtenido de «https://www.wikem.org/w/index.php?title=Medroxyprogesterone&oldid=372311»